JP2016536012A5 - - Google Patents

Download PDF

Info

Publication number
JP2016536012A5
JP2016536012A5 JP2016549206A JP2016549206A JP2016536012A5 JP 2016536012 A5 JP2016536012 A5 JP 2016536012A5 JP 2016549206 A JP2016549206 A JP 2016549206A JP 2016549206 A JP2016549206 A JP 2016549206A JP 2016536012 A5 JP2016536012 A5 JP 2016536012A5
Authority
JP
Japan
Prior art keywords
pkal
inhibitor
assay
subject
plasma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016549206A
Other languages
English (en)
Japanese (ja)
Other versions
JP6757252B2 (ja
JP2016536012A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/061247 external-priority patent/WO2015061183A1/en
Publication of JP2016536012A publication Critical patent/JP2016536012A/ja
Publication of JP2016536012A5 publication Critical patent/JP2016536012A5/ja
Application granted granted Critical
Publication of JP6757252B2 publication Critical patent/JP6757252B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016549206A 2013-10-21 2014-10-17 血漿カリクレイン系バイオマーカーを決定するためのアッセイ Active JP6757252B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361893505P 2013-10-21 2013-10-21
US61/893,505 2013-10-21
US201461939837P 2014-02-14 2014-02-14
US61/939,837 2014-02-14
PCT/US2014/061247 WO2015061183A1 (en) 2013-10-21 2014-10-17 Assays for determining plasma kallikrein system biomarkers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020144118A Division JP7135039B2 (ja) 2013-10-21 2020-08-28 血漿カリクレイン系バイオマーカーを決定するためのアッセイ

Publications (3)

Publication Number Publication Date
JP2016536012A JP2016536012A (ja) 2016-11-24
JP2016536012A5 true JP2016536012A5 (enExample) 2017-11-24
JP6757252B2 JP6757252B2 (ja) 2020-09-16

Family

ID=52993413

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016549206A Active JP6757252B2 (ja) 2013-10-21 2014-10-17 血漿カリクレイン系バイオマーカーを決定するためのアッセイ
JP2020144118A Active JP7135039B2 (ja) 2013-10-21 2020-08-28 血漿カリクレイン系バイオマーカーを決定するためのアッセイ
JP2022137393A Active JP7668772B2 (ja) 2013-10-21 2022-08-31 血漿カリクレイン系バイオマーカーを決定するためのアッセイ
JP2024117419A Pending JP2024150637A (ja) 2013-10-21 2024-07-23 血漿カリクレイン系バイオマーカーを決定するためのアッセイ

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020144118A Active JP7135039B2 (ja) 2013-10-21 2020-08-28 血漿カリクレイン系バイオマーカーを決定するためのアッセイ
JP2022137393A Active JP7668772B2 (ja) 2013-10-21 2022-08-31 血漿カリクレイン系バイオマーカーを決定するためのアッセイ
JP2024117419A Pending JP2024150637A (ja) 2013-10-21 2024-07-23 血漿カリクレイン系バイオマーカーを決定するためのアッセイ

Country Status (13)

Country Link
US (2) US11372002B2 (enExample)
EP (2) EP3808857B1 (enExample)
JP (4) JP6757252B2 (enExample)
KR (4) KR102521947B1 (enExample)
CN (1) CN105873951A (enExample)
AU (3) AU2014340450B2 (enExample)
BR (1) BR112016008970B1 (enExample)
CA (1) CA2927824C (enExample)
DK (1) DK3060582T3 (enExample)
ES (1) ES2837858T3 (enExample)
IL (3) IL289514B2 (enExample)
PL (1) PL3060582T3 (enExample)
WO (1) WO2015061183A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2905545T3 (es) 2010-01-06 2022-04-11 Takeda Pharmaceuticals Co Proteínas de unión a calicreína plasmática
KR102107695B1 (ko) * 2011-01-06 2020-05-07 다이액스 코포레이션 혈장 칼리크레인 결합 단백질
IL273688B2 (en) 2013-01-20 2024-12-01 Dyax Corp Evaluation and treatment of bradykinin-mediated disorders
ES2873204T3 (es) 2013-10-21 2021-11-03 Takeda Pharmaceuticals Co Diagnóstico y tratamiento de enfermedades autoinmunes
EP3808857B1 (en) 2013-10-21 2025-12-10 Takeda Pharmaceutical Company Limited Assays for determining plasma kallikrein system biomarkers
CN116585468A (zh) 2014-01-21 2023-08-15 武田药品工业株式会社 血浆激肽释放酶结合蛋白和其在治疗遗传性血管性水肿中的用途
IL247942B (en) 2014-03-27 2022-09-01 Dyax Corp Compositions and methods for drops in macular edema as a result of diabetes
KR102607829B1 (ko) * 2015-03-30 2023-12-01 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 저해제 및 유전성 혈관부종 발작을 예방하기 위한 이의 용도
ES2938089T3 (es) 2015-08-13 2023-04-04 Takeda Pharmaceuticals Co Tubos de extracción de sangre al vacío que contienen inhibidores de proteasa para la evaluación de la activación del sistema de contacto
EP3839514B1 (en) 2015-10-19 2023-12-13 Takeda Pharmaceutical Company Limited Immunoassay to detect cleaved high molecular weight kininogen
KR102874711B1 (ko) * 2015-12-15 2025-10-23 다케다 파머수티컬 컴패니 리미티드 전장 고분자량 키니노겐(hmwk) 및 절단된 hmwk를 구별하기 위한 펩타이드 정량화 검정법
CA3037154A1 (en) * 2016-09-16 2018-03-22 Dyax Corp. Protein biomarkers for diseases associated with the contact activation system
JP7319916B2 (ja) 2016-09-16 2023-08-02 武田薬品工業株式会社 遺伝性血管性浮腫のrnaバイオマーカー
MX2019002918A (es) * 2016-09-16 2019-07-18 Dyax Corp Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activacion por contacto.
EP3521828A1 (en) * 2018-01-31 2019-08-07 Centogene AG Method for the diagnosis of hereditary angioedema
WO2019165308A1 (en) * 2018-02-22 2019-08-29 The Regents Of The University Of California Threshold-stimulated plasma kallikrein activity as a biomarker for diagnosis of bradykinin-mediated angioedema
CN111057745B (zh) * 2019-12-30 2022-08-12 中国科学院生态环境研究中心 一种物质的血液毒性效应的高通量筛选方法
CN113777331A (zh) * 2020-06-09 2021-12-10 张曼 尿液激肽原-1及其多肽片段在烧伤中的应用
CN114166924B (zh) * 2021-12-03 2024-11-22 中国医学科学院北京协和医院 尿液蛋白标志物在诊断遗传性血管水肿中的用途
EP4548103A2 (en) * 2022-06-30 2025-05-07 Takeda Pharmaceutical Company Limited Protein biomarkers for lanadelumab treatment
WO2025153806A1 (en) * 2024-01-15 2025-07-24 Kalvista Pharmaceuticals Limited Methods for determining amidolytic activity

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1312564C (en) * 1985-07-12 1993-01-12 Robert W. Colman Monoclonal antibodies to human plasma prekallikrein and methods of preparing and using same
US4908431A (en) 1986-01-22 1990-03-13 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human kininogen and methods of preparing same
US5047323A (en) 1986-01-22 1991-09-10 Temple University Of The Commonwealth System Of Higher Education Method for detecting human kininogen using monoclonal antibodies thereto
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
JPS63185398A (ja) * 1986-09-10 1988-07-30 Nippon Zoki Pharmaceut Co Ltd 生理活性物質測定法
US4882272A (en) 1986-10-01 1989-11-21 Temple University - Of The Commonwealth System Of Higher Education High molecular weight kininogen assay
US5025796A (en) 1988-12-01 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Apparatus and methods for determining in vivo response to thermal stimulation in in an unrestrained subject
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
AU2548992A (en) 1991-08-13 1993-03-16 Temple University - Of The Commonwealth System Of Higher Education Modulation of blood pressure and inhibition of platelet activation with kininogen fragment
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
CA2180950C (en) 1994-01-11 2005-03-29 William Markland Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof
JPH1084995A (ja) 1996-09-12 1998-04-07 Nippon Zoki Pharmaceut Co Ltd 血液凝固第xii因子活性化法
US5789261A (en) 1996-10-30 1998-08-04 Temple University Of The Commonwealth System Of Higher Education Solid phase immunoassay
US6242210B1 (en) * 1997-05-20 2001-06-05 Actinova Limited Treatment of bacterial infections
JP4346798B2 (ja) 1999-08-19 2009-10-21 協和メデックス株式会社 Hcvコア抗原の検出または定量方法およびそれに用いる検出または定量試薬。
US6994852B1 (en) 1999-11-12 2006-02-07 Temple University-Of The Commonwealth System Of Higher Education Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5
US7067713B2 (en) * 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
US7678541B2 (en) 2000-11-21 2010-03-16 Hologic, Inc. Methods and compositions for the detection of a nucleic acid using a non-invasive cleavage reaction
JP2002221519A (ja) 2001-01-29 2002-08-09 Sysmex Corp 抗凝固剤およびそれを用いた抗凝固剤処理方法
US20040152633A1 (en) 2001-05-31 2004-08-05 Jorgensen Marianne Ulrich Kunitz-type sequences and polypeptides
US6913900B2 (en) * 2001-08-29 2005-07-05 Nippon Zoki Pharmaceutical Co., Ltd. Plasma prekallikrein activation and kallikrein production assay
EP1531791B1 (en) 2002-06-07 2010-08-11 Dyax Corp. Prevention and reduction of ischemia
AU2003281287A1 (en) 2002-07-04 2004-01-23 Oxford Glycosciences (Uk) Ltd Toxicity markers
US20070003552A1 (en) * 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
EP1598428A1 (en) * 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
CA2575791A1 (en) 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
EP1981519B1 (en) 2005-12-29 2017-12-27 Dyax Corp. Protease inhibition
US7276480B1 (en) 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
EP2051707B1 (en) 2006-07-31 2013-07-17 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
EP2089712A4 (en) 2006-11-22 2010-09-22 Life Technologies Corp BIOMARKERS OF AUTOIMMUNE DISEASES
EP2195010A4 (en) 2007-08-21 2012-03-14 Genzyme Corp TREATMENT WITH INHIBITORS OF KALLIKREINE
JP5424331B2 (ja) 2007-10-18 2014-02-26 国立大学法人 鹿児島大学 肝疾患診断用バイオマーカー
WO2009053050A1 (en) 2007-10-22 2009-04-30 Georg Dewald Disorders of vasoregulation and methods of diagnosing them
CA2729937A1 (en) 2008-07-07 2010-01-14 Nippon Zoki Pharmaceutical Co., Ltd. Fibromyalgia test method
EP2352762A1 (en) 2008-11-03 2011-08-10 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
US20110318359A1 (en) 2008-12-02 2011-12-29 Feener Edward P Method for reducing blood pressure using inhibitors of plasma kallikrein
US8637454B2 (en) 2009-01-06 2014-01-28 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
FR2942233B1 (fr) 2009-02-19 2015-03-13 Lfb Biotechnologies Moyens pour la purification d'une proteine du plasma sanguin, et procedes pour sa mise en oeuvre
KR101077275B1 (ko) 2009-05-07 2011-10-27 한국기초과학지원연구원 당단백질의 당쇄화를 이용한 암 진단 방법
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
US9206123B2 (en) 2009-12-18 2015-12-08 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
CA2783801A1 (en) 2009-12-18 2011-06-23 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
ES2905545T3 (es) 2010-01-06 2022-04-11 Takeda Pharmaceuticals Co Proteínas de unión a calicreína plasmática
EP2593121A2 (en) 2010-07-13 2013-05-22 University Of Rochester THE cAMP/PKA/HDAC5 PATHWAY AND USES THEREOF
AU2011336345B2 (en) 2010-12-02 2016-07-07 Becton, Dickinson And Company Blood collection devices containing blood stabilization agent
KR102107695B1 (ko) 2011-01-06 2020-05-07 다이액스 코포레이션 혈장 칼리크레인 결합 단백질
AU2012267546B2 (en) 2011-06-10 2015-12-24 Ionis Pharmaceuticals, Inc. Methods for modulating kallikrein (KLKB1) expression
WO2012170947A2 (en) 2011-06-10 2012-12-13 Isis Pharmaceuticals, Inc. Methods for modulating factor 12 expression
FR2983215B1 (fr) * 2011-11-28 2013-12-20 Univ Grenoble 1 Dosage de la capacite de controle de c1inh
IL273688B2 (en) 2013-01-20 2024-12-01 Dyax Corp Evaluation and treatment of bradykinin-mediated disorders
JP2016505159A (ja) 2013-02-01 2016-02-18 ベクトン・ディキンソン・アンド・カンパニーBecton, Dickinson And Company 接触経路抑制添加剤を含む血液採集装置
EP3808857B1 (en) 2013-10-21 2025-12-10 Takeda Pharmaceutical Company Limited Assays for determining plasma kallikrein system biomarkers
ES2873204T3 (es) 2013-10-21 2021-11-03 Takeda Pharmaceuticals Co Diagnóstico y tratamiento de enfermedades autoinmunes
CN116585468A (zh) 2014-01-21 2023-08-15 武田药品工业株式会社 血浆激肽释放酶结合蛋白和其在治疗遗传性血管性水肿中的用途
EP3839514B1 (en) 2015-10-19 2023-12-13 Takeda Pharmaceutical Company Limited Immunoassay to detect cleaved high molecular weight kininogen
KR102874711B1 (ko) 2015-12-15 2025-10-23 다케다 파머수티컬 컴패니 리미티드 전장 고분자량 키니노겐(hmwk) 및 절단된 hmwk를 구별하기 위한 펩타이드 정량화 검정법
US20230072523A1 (en) 2020-01-28 2023-03-09 Orgenesis Inc. Process and system for acellular therapy

Similar Documents

Publication Publication Date Title
JP2016536012A5 (enExample)
Pan et al. No evidence of severe acute respiratory syndrome–coronavirus 2 in semen of males recovering from coronavirus disease 2019
Ouyang et al. Dysregulated serum MiRNA profile and promising biomarkers in dengue-infected patients
Li et al. PPARγ interaction with UBR5/ATMIN promotes DNA repair to maintain endothelial homeostasis
Huang et al. Urinary Xist is a potential biomarker for membranous nephropathy
Hamaguchi et al. Origin of circulating free DNA in sepsis: analysis of the CLP mouse model
Xu et al. Cisplatin-induced downregulation of miR-199a-5p increases drug resistance by activating autophagy in HCC cell
Liao et al. Upregulation of FAM83D affects the proliferation and invasion of hepatocellular carcinoma
Brooks et al. The gut microbiome: a missing link in understanding the gastrointestinal manifestations of COVID-19?
Ye et al. The association of renin-angiotensin system genes with the progression of hepatocellular carcinoma
WO2014140933A8 (en) Method for the prognosis and treatment of cancer metastasis
JP2012500389A5 (enExample)
WO2007117444A3 (en) Protein detection by aptamers
BRPI1008957B8 (pt) método para detecção simultânea de uma pluralidade de ácidos nucleicos alvo executado por um sistema de análise integrada em tempo real de ácidos nucleicos alvo
JP2017500584A5 (enExample)
US10895572B2 (en) Autophagy-related nourin gene-based RNA network as early biomarkers for cardiac patients
Kovalenko et al. ROS production, intracellular HSP70 levels and their relationship in human neutrophils: effects of age
JP2015523569A5 (enExample)
BR112016019740A2 (pt) monitoramento do estado de inflamação
JP2015530868A5 (enExample)
Ehrnhoefer et al. Laquinimod decreases Bax expression and reduces caspase-6 activation in neurons
Ramsay et al. Blood transcriptomic biomarker as a surrogate of ischemic brain gene expression
JP7463351B2 (ja) 脳卒中の血液バイオマーカー
Menteşe et al. The diagnostic and prognostic significance of SCUBE1 levels in Crimean-Congo hemorrhagic fever
MX2016006782A (es) Un metodo para predecir la capacidad de respuesta a un tratamiento con un inhibidor del egfr.